GCG and type 2 diabetes mellitus: Up to now, scientists have proven that some of GLP-1 RA plays a role in protecting patients with T2DM and CVD from MACEs, including liraglutide [134, 135], efpeglenatide [136], dulaglutide (attenuate the risk of MACEs and non-cardiovascular death but not the all-cause death rate) [137, 138].